New AMRA Study Links Muscle Composition to Elevated Risk of Chronic Kidney Disease and Increased Mortality
AMRA Medical has released new research shedding light on an important and previously underappreciated factor influencing outcomes in patients with Chronic Kidney Disease. The study explores the relationship between adverse muscle composition (AMC) and mortality, revealing that this specific muscle phenotype is a powerful and independent predictor of all-cause mortality among individuals living with CKD.
The findings, published in the Clinical Journal of the American Society of Nephrology, are based on data derived from the UK Biobank imaging study. Together, these results reinforce the growing importance of advanced imaging biomarkers—particularly those derived from magnetic resonance imaging (MRI)—in identifying high-risk patients and improving disease stratification across chronic conditions.
At the core of the study is the concept of adverse muscle composition, a phenotype defined by two key characteristics: reduced muscle volume relative to expected norms (expressed as a low muscle volume Z-score) and increased fat infiltration within muscle tissue. This combination reflects not only diminished muscle mass but also compromised muscle quality, both of which appear to play a critical role in disease progression and patient outcomes.
To investigate this relationship, researchers from AMRA collaborated with scientists at Linköping University. Using AMRA’s proprietary MRI-based body composition analysis platform, the team evaluated 894 individuals diagnosed with chronic kidney disease. The analysis focused on quantifying fat-free thigh muscle volume as well as muscle fat infiltration (MFI), two metrics that together provide a detailed picture of muscle health.
The results revealed that approximately 30% of the study population met the criteria for adverse muscle composition. This substantial proportion highlights AMC as a relatively common phenotype within the CKD population, rather than a rare or niche condition. More importantly, the presence of AMC was strongly associated with an increased risk of mortality.
Over an average follow-up period of 3.6 years, individuals identified as having AMC experienced significantly higher rates of all-cause mortality compared to those without this phenotype. The unadjusted hazard ratio was calculated at 6.17, indicating that patients with AMC were more than six times as likely to die from any cause during the study period. Even after adjusting for a range of confounding variables—including demographic characteristics, lifestyle factors and clinical conditions—the association remained robust, with a hazard ratio of 4.21.
These findings underscore the strength and independence of AMC as a prognostic marker. Unlike many traditional risk factors, which may only capture specific aspects of disease severity or apply to limited patient subsets, adverse muscle composition appears to offer a more comprehensive view of patient risk. By combining measures of both muscle quantity and quality, AMC provides a multidimensional assessment that can better reflect the complexity of chronic kidney disease.
The implications of this research extend beyond risk prediction. By identifying a large subgroup of patients who share a common and measurable phenotype associated with poor outcomes, AMC may also serve as a valuable tool for improving clinical trial design. Researchers and clinicians could use this information to stratify patients more effectively, ensuring that interventions are tested in populations most likely to benefit or to experience adverse outcomes.
Moreover, the use of MRI-based muscle composition analysis introduces a level of precision and standardization that is difficult to achieve with conventional assessment methods. Traditional markers, such as body mass index (BMI) or basic laboratory values, often fail to capture the nuanced changes in muscle structure and function that occur in chronic disease. In contrast, MRI-derived biomarkers provide high-resolution, reproducible data that can be consistently applied across different studies and patient populations.
This study also contributes to a broader and rapidly expanding body of evidence supporting the role of muscle composition in chronic disease management. Increasingly, researchers are recognizing that muscle health is not merely a secondary concern but a central determinant of outcomes in a wide range of conditions. AMRA has been actively involved in advancing this field through studies spanning multiple indications, including metabolic dysfunction-associated steatotic liver disease (MASLD), heart failure and advanced liver conditions such as End-Stage Liver Disease.
By applying standardized MRI-based methodologies across these diverse disease areas, AMRA is helping to establish a unified framework for evaluating muscle composition. This consistency enables meaningful comparisons across studies and supports the development of more integrated approaches to patient care. It also facilitates the identification of common pathways linking muscle health to disease progression, potentially opening the door to new therapeutic strategies.
Importantly, the current findings build on earlier research examining muscle composition in patients with chronic kidney disease, including studies involving individuals undergoing hemodialysis. These previous investigations have similarly highlighted the relationship between poor muscle quality and adverse outcomes, suggesting that AMC may be relevant across different stages of CKD progression.
Taken together, the accumulating evidence points to muscle composition as a critical, yet often overlooked, component of chronic disease management. For clinicians, incorporating muscle biomarkers into routine assessment could enhance the ability to identify high-risk patients and tailor treatment strategies accordingly. For researchers, these biomarkers offer a powerful tool for improving the design and interpretation of clinical trials.
The study’s conclusions also raise important questions about the potential for targeted interventions aimed at improving muscle health. If adverse muscle composition is indeed a modifiable risk factor, then therapies focused on increasing muscle mass, reducing fat infiltration or improving overall muscle function could play a significant role in reducing mortality and improving quality of life for patients with CKD and other chronic conditions.
Looking ahead, further research will be needed to explore these possibilities and to determine how best to integrate muscle composition analysis into clinical practice. Larger studies, longer follow-up periods and interventional trials will be essential for confirming the findings and translating them into actionable strategies.
In summary, the research conducted by AMRA Medical and its collaborators provides compelling evidence that adverse muscle composition is a strong and independent predictor of mortality in chronic kidney disease. By leveraging advanced MRI-based technologies, the study highlights the value of detailed muscle assessment in identifying high-risk patients and advancing our understanding of disease dynamics. As the healthcare community continues to seek more precise and personalized approaches to care, muscle composition is emerging as a key factor that cannot be ignored.
About AMRA Medical
AMRA Medical is a global leader in health informatics, pioneering fat and muscle analysis with its proprietary, MRI-based technologies. Our gold-standard platform delivers highly accurate and standardized biomarkers, enabling a profound understanding of metabolic and musculoskeletal health that goes beyond traditional body composition metrics. These insights play a crucial role in optimizing clinical trial design, improving endpoint selection, and supporting data-driven decision-making in both research and clinical practice.
AMRA’s solutions are based on rigorous scientific principles and continuous innovation, and are designed to meet the complex demands of modern healthcare and pharmaceutical development. Through standardized, cloud-based workflows and strategic collaboration, we enable our partners to have clear and secure access to actionable data – accelerating progress from early discovery to impactful clinical outcomes.
The original language in which the text is published is the official and authorized version. Translations are provided for convenience only. Only the original language version is legally valid. Therefore, please compare translations with the original language version of the publication.
Source Link:https://www.businesswire.com/
